CClinicalTrials.gg
CompletedNCT03745118Updated Nov 13, 2023

Development of a Practical, Minimally Invasive Seizure Gauge

An interventional study of EpiTel EpiLog and Byte Flies Sensor Dots in Epilepsy, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 7 Years and older. Per ClinicalTrials.gov, last updated 2023-11-13.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
95
Allocation
Not applicable
Ages
7 Years and older
Sex
All
01

Study summary

The researchers are trying to assess changes in physiological signals before and during seizures.

Read the detailed description

Subjects that are undergoing video EEG monitoring in the hospital for their epilepsy at Mayo Clinic will be consented to participate in this study for a minimum of two days and/or the duration of their hospital stay for their clinical care. Subjects will be asked to wear up to 4 different commercially available seizure detection devices and complete surveys.

In the second year of the study patients who have implanted devices capable of recording or detecting seizures will be recruited to wear a noninvasive biosensor for multiple months. This data will be used to develop algorithms capable of detecting and/or forecasting seizures.

When the subjects clinical EEG monitoring is completed data scientists will analyze the data to identify patterns.

02

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Seizure
03

In context

Seizures

881 studies on the registry are indexed under Seizures; 143 are open to participants now.

This study's enrollment of 95 is above the median of 64 across 610 interventional studies indexed under Seizures.

Browse Seizures studies →

Lead sponsor

Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.

Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with epilepsy- scalp EEG or invasive EEG monitoring for clinical care, or an implanted device capable of monitoring brain activity and identifying seizures (e.g. NeuroPace RNS, Medtronic PC+S, Medtronic RC+S)
  • Pediatric subjects 7 years of age or older.

Exclusion criteria

Exclusion Criteria:

  • Cognitive or psychiatric condition rendering patient unable to cooperate with data collection, or manage and recharge smart watch and tablet computer devices.
  • Presence of open or healing wounds near monitoring sites (infection risk).
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Other
    Monitoring Device

    Subjects will be asked to wear up to 4 different noninvasive seizure detection devices including EpiTel EpiLog, Byte Flies Sensor Dots, Empatica E4, Biovotion Everion, GeneActiv

    Device: EpiTel EpiLog · Device: Byte Flies Sensor Dots · Device: Empatica E4 · Device: Biovotion Everion · Device: GeneActiv

Interventions

  • DeviceEpiTel EpiLog

    Plastic pad that is about the size of a house key, and will be adhered to your scalp with gel

    Also known as: Epilog

  • DeviceByte Flies Sensor Dots

    Plastic pads that will be adhered to your chest area

    Also known as: Byteflies, Sensor Dots

  • DeviceEmpatica E4

    wearable seizure detection wristband

    Also known as: E4 Wristband

  • DeviceBiovotion Everion

    wearable seizure detection device armband that is attached to upper arm

  • DeviceGeneActiv

    wearable seizure detection watch

06

What researchers measure

Primary outcomes

  1. Assessment of Physiological Signals Measurable with Wearable Sensors

    We will collect physiological signals with the five wearable, noninvasive biosensors listed below in Mayo patients undergoing scalp-recorded video EEG and invasive stereotactic EEG/video monitoring as part of their clinical epilepsy evaluation. We will evaluate biosignals based on data quality and reliability, and subject comfort and ease of use.

    Time frame: 2-10 days approximately

  2. Pattern Analysis

    We will apply data mining and machine learning methods to search for patterns in the collected physiological signals and correlate these patterns with the timing of seizures identified by the patient's clinical video-EEG monitoring.

    Time frame: 2-10 days approximately

07

Study locations

1 site
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03745118
Lead sponsor
Mayo Clinic
Responsible party
Benjamin H. Brinkmann (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Nov 19, 2018
Start date
Nov 19, 2018
Primary completion
Aug 5, 2022
Completion
Aug 5, 2022
Last update
Nov 13, 2023

Study contacts

Benjamin (Ben) H. Brinkmann, Ph.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion